Patents Issued in September 15, 2020
-
Patent number: 10772866Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder and central nervous system diseases containing fluoxetine and vitamin C as active ingredients.Type: GrantFiled: April 28, 2016Date of Patent: September 15, 2020Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITYInventors: Tae Young Yune, Hyung-Hwan Baik, Jee Youn Lee, Sam Kim
-
Patent number: 10772867Abstract: A method of treating hyperhidrosis in a mammalian subject, said method comprising topically administering a composition comprising a compound having the formula (I): wherein R is methyl or ethyl, said compound having the R stereoisomeric configuration at the 2 position and the R, S, or RS stereoisomeric configuration at the 1? and 3? position, or being a mixture thereof; in an amount of from about 1.0% to about 25% of said compound, an additional active substance that is an antiperspirant active substance and, optionally, a pharmaceutically acceptable vehicle, to skin of an area of a mammalian subject suffering from hyperhidrosis in a one to four times daily dosing regimen.Type: GrantFiled: July 2, 2019Date of Patent: September 15, 2020Assignee: BODOR LABORATORIES, INC.Inventors: Nicholas S. Bodor, David Angulo
-
Patent number: 10772868Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.Type: GrantFiled: January 8, 2019Date of Patent: September 15, 2020Assignee: Silvergate Pharmaceuticals, Inc.Inventors: Gerold L. Mosher, David W. Miles
-
Patent number: 10772869Abstract: The present disclosure provides oral liquid compositions including carvedilol with enhanced solubility and stability. Also provided herein are methods of using oral liquid compositions for the treatment of hypertension, treatment of heart failure, and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.Type: GrantFiled: January 15, 2020Date of Patent: September 15, 2020Assignee: ECI Pharmaceuticals, LLCInventors: Nirali R. Bhatt, Solomon Goll
-
Patent number: 10772870Abstract: The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (IPF), emphysema of the lungs, chronic obstructive pulmonary disease (COPD) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on Treamide. The latter is a bisamide derivative of dicarboxylic acid of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 14, 2018Date of Patent: September 15, 2020Assignee: Treamid Therapeutics GmbHInventors: Vladimir Evgenievich Nebolsin, Anastasia Vladimirovna Rydlovskaya, Alexandr Mikhailovich Dygai, Tatiana Gennadievna Borovskaya, Evgenii Germanovich Skurikhin
-
Patent number: 10772871Abstract: Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.Type: GrantFiled: October 3, 2014Date of Patent: September 15, 2020Assignee: Teikoku Pharma USA, Inc.Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
-
Patent number: 10772872Abstract: Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R5, R6, R8, R9, R11, X1, and X2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Frost Biologic, Inc.Inventor: Adam Siddiqui-Jain
-
Patent number: 10772873Abstract: Dietary supplement compositions directed to men and women and to the maintenance and improvement of human physiology, including weight, skin, hair, and general organ function and sexual health.Type: GrantFiled: August 26, 2019Date of Patent: September 15, 2020Assignee: SERENDIPITY TECHNOLOGIES LLCInventor: Amen Dhyllon
-
Patent number: 10772874Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.Type: GrantFiled: August 12, 2019Date of Patent: September 15, 2020Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
-
Patent number: 10772875Abstract: The present invention relates to agents enhancing HuR/ELAV levels for use in the treatment of BRAF-mutated cancers and uses thereof. In particular, the invention relates to the use of agents enhancing HuR/ELAV levels in combination with BRAF inhibitors for the treatment of BRAF-mutated cancers, in particular melanoma and to methods for identifying agents useful for potentiating the effects of BRAF inhibitors, when used in combination.Type: GrantFiled: March 14, 2018Date of Patent: September 15, 2020Assignee: LES HOPITAUX UNIVERSITAIRES DE GENEVEInventor: Rastine Mérat
-
Patent number: 10772876Abstract: The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer, squamous cell carcinoma, cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas, muscular disorders muscular dystrophy and impaired regeneration capacity after injury; use in immunotherapy for cancer.Type: GrantFiled: March 17, 2017Date of Patent: September 15, 2020Assignee: Xeniopro GmbHInventors: Viktoria Reinmueller, Jieping Zhu
-
Patent number: 10772877Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.Type: GrantFiled: February 7, 2020Date of Patent: September 15, 2020Assignee: XSPRAY MICROPARTICLES ABInventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
-
Patent number: 10772878Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.Type: GrantFiled: December 29, 2017Date of Patent: September 15, 2020Assignee: Dekk-Tec, Inc.Inventor: Lee Roy Morgan
-
Patent number: 10772879Abstract: This invention relates to pharmaceutical formulations comprising 1-(2-thien-2?-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2?-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.Type: GrantFiled: April 5, 2016Date of Patent: September 15, 2020Assignee: Torrent Pharmaceuticals LimitedInventors: Chaitanya Dutt, Jaya Abraham, Vivek Mishra, Amit Kesarwani, Ramesh Chandra Gupta, Shailesh Deshpande, Shital Kumar Zambad, Anoop Mathur, Jignesh Kotecha, Sachin Latad, Manish Patel, Anita Chaudhari
-
Patent number: 10772880Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.Type: GrantFiled: June 4, 2019Date of Patent: September 15, 2020Assignee: VANDA PHARMACEUTICALS INC.Inventors: Mihael H. Polymeropoulos, Louis William Licamele
-
Patent number: 10772881Abstract: Provided herein are quinolines, e.g., a compound of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. Also provided herein are methods of their use for modulating the activity of a sarcoplasmic/endoplasmic reticulum C2+ ATPase.Type: GrantFiled: January 25, 2019Date of Patent: September 15, 2020Inventor: Russell Dahl
-
Patent number: 10772882Abstract: A problem to be solved by the present invention is to provide a novel preventive or therapeutic agent for pulmonary hypertension containing as an active ingredient a compound that has not been known for a therapeutic effect on pulmonary hypertension heretofore. The present invention provides a preventive or therapeutic agent for pulmonary hypertension containing emetine or a salt thereof.Type: GrantFiled: March 28, 2017Date of Patent: September 15, 2020Assignee: TOHOKU UNIVERSITYInventors: Hiroaki Shimokawa, Hidetoshi Tokuyama, Hirofumi Ueda, Jyunken Aoki, Takayuki Doi, Kuniyuki Kano, Kimio Satoh, Ryo Kurosawa
-
Patent number: 10772883Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.Type: GrantFiled: March 17, 2017Date of Patent: September 15, 2020Assignee: MannKind CorporationInventors: Marshall L. Grant, Grayson W. Stowell, Paul Menkin, John J. Freeman, Jr.
-
Patent number: 10772884Abstract: The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.Type: GrantFiled: August 27, 2019Date of Patent: September 15, 2020Assignees: Alzprotect, Universite De Lille 2 Droit Et Sante, INSERM (Institut National De La Sante Et De La Recherche)Inventors: Stéphane Burlet, Cécilia Estrella, Mathieu Barrier, Patricia Melnyk, Nicolas Sergeant, Luc Buee, Philippe Verwaerde
-
Patent number: 10772885Abstract: The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition comprises nintedanib, or its salt, derivative, analog or polymorph, or combination thereof. The disclosure also relates to pharmaceutical composition or formulation, which can be used for treating ocular diseases. In another aspect, the disclosure provides method of making the pharmaceutical composition or formulation.Type: GrantFiled: May 19, 2017Date of Patent: September 15, 2020Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD.Inventors: Shuhua Guo, Jiewen Zhong, Xinting Yuan, Zongren Yao
-
Patent number: 10772886Abstract: N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methyl-azetidine-1-sulfonamide (compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.Type: GrantFiled: March 9, 2017Date of Patent: September 15, 2020Assignee: ARDEA BIOSCIENCES, INC.Inventors: Payal Nanavati, Jeffrey Miner
-
Patent number: 10772887Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.Type: GrantFiled: August 2, 2017Date of Patent: September 15, 2020Assignee: Kagoshima UniversityInventors: Daisuke Kodama, Shuji Izumo
-
Patent number: 10772888Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.Type: GrantFiled: April 10, 2017Date of Patent: September 15, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
-
Patent number: 10772889Abstract: A liquid nutritional composition including 5-methyltetrahydrofolic acid (5-MTHF) is provided. The liquid nutritional composition also includes ascorbic acid and a protein system containing methionine to inhibit or reduce oxidation of the 5-MTHF and provide an active folate level of the liquid nutritional composition that remains stable over the shelf life of the liquid nutritional composition.Type: GrantFiled: December 19, 2016Date of Patent: September 15, 2020Assignee: ABBOTT LABORATORIESInventors: Paul Johns, Jeffrey Baxter, Megan Terp, Normanella Dewille, Youngsuk Heo
-
Patent number: 10772890Abstract: The present invention relates to the use of myeloperoxidase inhibitors (MPO) inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.Type: GrantFiled: August 30, 2018Date of Patent: September 15, 2020Assignee: AstraZeneca ABInventors: Hakan Eriksson, Werner Poewe
-
Patent number: 10772891Abstract: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).Type: GrantFiled: April 23, 2018Date of Patent: September 15, 2020Assignee: GENKYOTEX SUISSE SAInventors: Patrick Page, Mike Orchard, Benoit Laleu, Francesca Gaggini
-
Patent number: 10772892Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.Type: GrantFiled: June 13, 2019Date of Patent: September 15, 2020Assignee: Zenith Epigenetics Ltd.Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 10772894Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 26, 2018Date of Patent: September 15, 2020Assignee: Resverlogix Corp.Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Henrik C. Hansen
-
Patent number: 10772895Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition.Type: GrantFiled: September 20, 2018Date of Patent: September 15, 2020Assignee: FUJIFILM CORPORATIONInventors: Hiroki Tanisaka, Kyoko Senga, Shuhei Osaka
-
Patent number: 10772896Abstract: Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.Type: GrantFiled: August 27, 2018Date of Patent: September 15, 2020Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio Cafiero, Leonardo Ortenzi, Francesca Schiaretti
-
Patent number: 10772897Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.Type: GrantFiled: December 21, 2018Date of Patent: September 15, 2020Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
-
Patent number: 10772898Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.Type: GrantFiled: December 17, 2018Date of Patent: September 15, 2020Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Michael B. Yaffe, Jesse C. Patterson
-
Patent number: 10772899Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: September 5, 2019Date of Patent: September 15, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman
-
Patent number: 10772900Abstract: The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.Type: GrantFiled: July 21, 2017Date of Patent: September 15, 2020Assignee: The Trustees of The University of PennsylvaniaInventors: Daniel P. Beiting, Ana M. Misic, Shelly C. Rankin
-
Patent number: 10772901Abstract: Provided is a pharmaceutical composition for use in a method of preventing or treating a urinary tract infection (UTI), chronic cystitis, overactive bladder, partial bladder obstruction or urethritis, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, where in said method said composition is administered intraurethrally, intravesically, intraureterally and/or intrarenally, as well as a pharmaceutical composition for use in a method of preventing or treating bladder cancer, where in said method said composition is administered intravesically, said composition comprising one or more oligomeric tannins, selected from proanthocyanidins and/or hydrolysable tannins, wherein said tannins are bound to an anti-cancer agent and/or liposomes containing an anti-cancer agent, together with compositions related thereto.Type: GrantFiled: September 18, 2017Date of Patent: September 15, 2020Assignees: UroPharma Limited, Synesis LLCInventors: Howard Shapland, Scott Glickman, Christian G. Krueger, Amy B. Howell, Jess D. Reed
-
Patent number: 10772902Abstract: The present disclosure provides: floridoside or isethionic acid for use as an antibiotic potentiator; floridoside or isethionic acid in a combination therapy with an antibiotic compound; as well as methods of potentiating the antibiotic activity of an antibiotic compound, where the method comprises administering floridoside or isethionic acid to an animal or plant.Type: GrantFiled: January 27, 2017Date of Patent: September 15, 2020Assignee: OCELAND BIOLOGICALS LIMITEDInventors: Balakrishnan Prithiviraj, Garima Kulshrestha
-
Patent number: 10772903Abstract: Described herein are methods for the treatment of cancer by modulating fungal populations to enhance the therapeutic response to a cancer therapy. In particular, the present invention discloses modulating the fungal microbiome in combination with a cancer therapy to enhance the anti-tumor effect.Type: GrantFiled: September 12, 2017Date of Patent: September 15, 2020Assignee: Cedars-Sinai Medical CenterInventors: Stephen Shiao, David Underhill
-
Patent number: 10772904Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.Type: GrantFiled: July 22, 2019Date of Patent: September 15, 2020Assignee: THOMAS JEFFERSON UNIVERSITYInventors: David W. Andrews, Douglas C. Hooper
-
Patent number: 10772905Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.Type: GrantFiled: August 2, 2019Date of Patent: September 15, 2020Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
-
Patent number: 10772906Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: GrantFiled: February 12, 2019Date of Patent: September 15, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 10772907Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.Type: GrantFiled: August 30, 2019Date of Patent: September 15, 2020Assignee: IDERA PHARMACEUTICALS, INC.Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
-
Patent number: 10772908Abstract: A mucoadhesive formulation containing a clathrate host that encloses water molecules provides an effective means for, not only providing moisture to, and maintaining moisture on, a mucosal surface, but also in maintaining a high concentration of a sugar alcohol in situ on the mucosal surface for extended periods of time.Type: GrantFiled: November 20, 2015Date of Patent: September 15, 2020Assignee: ELEVATE ORAL CARE, LLCInventor: Jerome E. Swanson
-
Patent number: 10772909Abstract: Shown and described is an insulin-mimetic as an inductive agent for cartilage and/or bone repair is disclosed. Sodium tungstate (Na2WO4) was utilized as an inductive factor to enhance human mesenchymal stem cell (MSC) chondrogenesis. The chondrogenic differentiation of MSCs was enhanced in the presence of low concentrations of Na2WO4 as compared to control, without Na2WO4. Also disclosed is a composite scaffold capable of supporting cell and tissue growth. The composite scaffold could include zinc oxide and polycaprolactone.Type: GrantFiled: October 2, 2017Date of Patent: September 15, 2020Assignee: New Jersey Institute of TechnologyInventors: Treena Lynne Arinzeh, Ateka Khader
-
Patent number: 10772910Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, the pharmaceutical composition including a graphene nanostructure as an active ingredient.Type: GrantFiled: June 11, 2018Date of Patent: September 15, 2020Assignees: Seoul National University R&DB Foundation, The Johns Hopkins UniversityInventors: Byung Hee Hong, Je Min Yoo, Hanseok Ko, Donghoon Kim
-
Patent number: 10772911Abstract: A pharmaceutical formulation comprising exosomes derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising a microvesicles derived from mobilized stem cells, and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles. A pharmaceutical formulation comprising an exosome-derived and/or microvesicle derived molecule and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles.Type: GrantFiled: March 24, 2015Date of Patent: September 15, 2020Assignee: Advanced ReGen Medical Technologies, LLCInventors: Steven John Greco, Vincent C. Giampapa
-
Patent number: 10772912Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.Type: GrantFiled: February 28, 2019Date of Patent: September 15, 2020Assignee: NantKwest, Inc.Inventors: Hans G. Klingemann, Barry J. Simon
-
Patent number: 10772913Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.Type: GrantFiled: April 2, 2019Date of Patent: September 15, 2020Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: George Georgiou, Everett Stone
-
Patent number: 10772914Abstract: Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.Type: GrantFiled: April 18, 2019Date of Patent: September 15, 2020Assignee: Baylor College of MedicineInventors: Cliona M. Rooney, Sandhya Sharma
-
Patent number: 10772915Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: February 5, 2020Date of Patent: September 15, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou